|
1
|
Richardson TE, Walker JM, Hambardzumyan D,
Brem S, Hatanpaa KJ, Viapiano MS, Pai B, Umphlett M, Becher OJ,
Snuderl M, et al: Genetic and epigenetic instability as an
underlying driver of progression and aggressive behavior in
IDH-mutant astrocytoma. Acta Neuropathol. 148:52024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ezzati S, Salib S, Balasubramaniam M and
Aboud O: Epidermal growth factor receptor inhibitors in
glioblastoma: Current status and future possibilities. Int J Mol
Sci. 25:23162024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Testa U, Castelli G and Pelosi E: CAR-T
Cells in the treatment of nervous system tumors. Cancers (Basel).
16:29132024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo X, Gu L, Li Y, Zheng Z, Chen W, Wang
Y, Wang Y, Xing H, Shi Y, Liu D, et al: Histological and molecular
glioblastoma, IDH-wildtype: A real-world landscape using the 2021
WHO classification of central nervous system tumors. Front Oncol.
13:12008152023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tan AC, Ashley DM, López GY, Malinzak M,
Friedman HS and Khasraw M: Management of glioblastoma: State of the
art and future directions. CA Cancer J Clin. 70:299–312. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Agarwal A, Edgar MA, Desai A, Gupta V,
Soni N and Bathla G: Molecular GBM versus Histopathological GBM:
Radiology-pathology-genetic correlation and the new WHO 2021
definition of glioblastoma. AJNR Am J Neuroradiol. 45:1006–1012.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ostrom QT, Cioffi G, Waite K, Kruchko C
and Barnholtz-Sloan JS: CBTRUS Statistical Report: Primary brain
and other central nervous system tumors diagnosed in the United
States in 2014–2018. Neuro Oncol. 23:iii1–iii105. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yi GZ, Zhang HY, Que TS, Qu SQ, Li ZY, Qi
ST, Feng WY and Huang GL: Identification of the clinical and
genetic characteristics of gliomas with gene fusions by integrated
genomic and transcriptomic analysis. Eur J Med Res. 30:492025.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ungan G, Pons-Escoda A, Ulinic D, Arús C,
Ortega-Martorell S, Olier I, Vellido A, Majós C and Julià-Sapé M:
Early pseudoprogression and progression lesions in glioblastoma
patients are both metabolically heterogeneous. NMR Biomed.
37:e50952024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thornton ZA, Andrews LJ, Zhao H, Zheng J,
Paternoster L, Robinson JW and Kurian KM: Brain multi-omic
Mendelian randomisation to identify novel drug targets for
gliomagenesis. Hum Mol Genet. 34:178–192. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brennan CW, Verhaak RG, McKenna A, Campos
B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ,
Berman SH, et al: The somatic genomic landscape of glioblastoma.
Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karipidis K, Baaken D, Loney T, Blettner
M, Mate R, Brzozek C, Elwood M, Narh C, Orsini N, Röösli M, et al:
The effect of exposure to radiofrequency fields on cancer risk in
the general and working population: A systematic review of human
observational studies-Part I: Most researched outcomes. Environ
Int. 191:1089832024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Q, Hu B, Hu X, Kim H, Squatrito M,
Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, et al: Tumor
evolution of Glioma-intrinsic gene expression subtypes associates
with immunological changes in the microenvironment. Cancer Cell.
33:1522018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luo J, Junaid M, Hamid N, Duan JJ, Yang X
and Pei DS: Current understanding of gliomagenesis: From model to
mechanism. Int J Med Sci. 19:2071–2079. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Senhaji N, Squalli Houssaini A, Lamrabet
S, Louati S and Bennis S: Molecular and Circulating Biomarkers in
Patients with Glioblastoma. Int J Mol Sci. 23:74742022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grewal EP, Richardson LGK, Sun J,
Ramapriyan R, Martinez-Lage M, Miller JJ, Carter BS, Cahill DP,
Curry WT and Choi BD: Mutant IDH modulates suppressive myeloid
populations in malignant glioma. Clin Cancer Res. 30:4068–4076.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lucas CG, Al-Adli NN, Young JS, Gupta R,
Morshed RA, Wu J, Ravindranathan A, Shai A, Oberheim Bush NA,
Taylor JW, et al: Longitudinal multimodal profiling of IDH-wildtype
glioblastoma reveals the molecular evolution and cellular
phenotypes underlying prognostically different treatment responses.
Neuro Oncol. 27:89–105. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du X and Hu H: The Roles of
2-hydroxyglutarate. Front Cell Dev Biol. 9:6513172021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hou Z, Wu H, Luo N, Li S, Zhang X, Dong S,
Zhu D, Zhang H and Tao R: Almonertinib combined with anlotinib and
temozolomide in a patient with recurrent glioblastoma with EGFR
L858R mutation. Oncologist. 28:449–452. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sai Krishna AVS, Sinha S, Satyanarayana
Rao MR and Donakonda S: The impact of PTEN status on glioblastoma
multiforme: A glial cell type-specific study identifies unique
prognostic markers. Comput Biol Med. 184:1093952025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xia Q, Zhang H, Zhang P, Li Y, Xu M, Li X,
Li X and Dong L: Oncogenic Smurf1 promotes PTEN wild-type
glioblastoma growth by mediating PTEN ubiquitylation. Oncogene.
39:5902–5915. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mazzoleni A, Awuah WA, Sanker V, Bharadwaj
HR, Aderinto N, Tan JK, Huang HYR, Poornaselvan J, Shah MH, Atallah
O, et al: Chromosomal instability: A key driver in glioma
pathogenesis and progression. Eur J Med Res. 29:4512024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ghosh D, Pryor B and Jiang N: Cellular
signaling in glioblastoma: A molecular and clinical perspective.
Int Rev Cell Mol Biol. 386:1–47. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pham J, Cote DJ, Kang K, Briggs RG, Gomez
D, Prasad A, Daggupati S, Sisti J, Chow F, Attenello F, et al:
Treatment practices and survival outcomes for IDH-wildtype
glioblastoma patients according to MGMT promoter methylation
status: Insights from the U.S. National Cancer Database. J
Neurooncol. Feb 5–2025.doi: 10.1007/s11060-025-04952-y (Epub ahead
of print). View Article : Google Scholar
|
|
26
|
Fathi Kazerooni A, Bakas S, Saligheh Rad H
and Davatzikos C: Imaging signatures of glioblastoma molecular
characteristics: A radiogenomics review. J Magn Reson Imaging.
52:54–69. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stazi G, Taglieri L, Nicolai A, Romanelli
A, Fioravanti R, Morrone S, Sabatino M, Ragno R, Taurone S,
Nebbioso M, et al: Dissecting the role of novel EZH2 inhibitors in
primary glioblastoma cell cultures: Effects on proliferation,
epithelial-mesenchymal transition, migration, and on the
pro-inflammatory phenotype. Clin Epigenetics. 11:1732019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bates SE: Epigenetic therapies for cancer.
N Engl J Med. 383:650–663. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meng W, Wang B, Mao W, Wang J, Zhao Y, Li
Q, Zhang C, Tang Y and Ma J: Enhanced efficacy of histone
deacetylase inhibitor combined with bromodomain inhibitor in
glioblastoma. J Exp Clin Cancer Res. 37:2412018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yuan Z, Zhou Y, Gao S, Cheng Y and Li Z:
Homogeneous and sensitive detection of microRNA with ligase chain
reaction and lambda exonuclease-assisted cationic conjugated
polymer biosensing. ACS Appl Mater Interfaces. 6:6181–6185. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dai SM, Li FJ, Long HZ, Zhou ZW, Luo HY,
Xu SG and Gao LC: Relationship between miRNA and ferroptosis in
tumors. Front Pharmacol. 13:9770622022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Charbit H and Lavon I: Investigating
expression dynamics of miR-21 and miR-10b in glioblastoma cells in
vitro: Insights into responses to hypoxia and secretion mechanisms.
Int J Mol Sci. 25:79842024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su
JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits
glioblastoma tumorigenesis and metastasis by suppressing the
expression of IGF2BP1. J Biol Chem. 290:8938–8948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rhim J, Baek W, Seo Y and Kim JH: From
molecular mechanisms to therapeutics: Understanding MicroRNA-21 in
cancer. Cells. 11:27912022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Y, Rabinovsky R, Wei Z, El Fatimy R,
Deforzh E, Luan B, Peshkin L, Uhlmann EJ and Krichevsky AM:
Secreted PGK1 and IGFBP2 contribute to the bystander effect of
miR-10b gene editing in glioma. Mol Ther Nucleic Acids. 31:265–275.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tan C, Wei J, Li Z, Tian N, Wang Z, Wang
G, Han L and Tian Y: Circ_0021350 plays an oncogene role by
regulating miR-1207-3p/PIK3R3 in glioblastoma. BMC Cancer.
23:8082023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu H, Li C, Yang J, Sun Y, Zhang S, Yang
J, Yang L, Wang Y and Jiao B: Long noncoding RNA
CASC9/miR-519d/STAT3 positive feedback loop facilitate the glioma
tumourigenesis. J Cell Mol Med. 22:6338–6344. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang G, Lin X, Han H, Zhang H, Li X, Feng
M and Jiang C: lncRNA H19 promotes glioblastoma multiforme
development by activating autophagy by sponging miR-491-5p.
Bioengineered. 13:11440–11455. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yao H, Huang C, Zou J, Liang W, Zhao Y,
Yang K, Zhong Z, Zhou S, Li J, Li Y, et al: Extracellular
vesicle-packaged lncRNA from cancer-associated fibroblasts promotes
immune evasion by downregulating HLA-A in pancreatic cancer. J
Extracell Vesicles. 13:e124842024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao J, Jin W, Yi K, Wang Q, Zhou J, Tan
Y, Xu C, Xiao M, Hong B, Xu F, et al: Combination LSD1 and
HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces
apoptosis in glioblastoma cells. Pharmacol Res. 171:1057642021.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Yu Y, Yu J, Wang C, Wang Y, Fu R
and Zhang C: The role of the dysregulation of circRNAs expression
in glioblastoma multiforme. J Mol Neurosci. 75:92025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Alom MW, Jibon MDK, Faruqe MO, Rahman MS,
Akter F, Ali A and Rahman MM: Integrated gene expression
Data-driven identification of molecular signatures, prognostic
biomarkers, and drug targets for glioblastoma. Biomed Res Int.
2024:68102002024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang S, Gao S and Dong Z: CircVCAN
promotes glioma progression through the miR-488-3p/MEF2C-JAGGED1
axis. Environ Toxicol. 39:4417–4430. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kadoch C and Crabtree GR: Mammalian
SWI/SNF chromatin remodeling complexes and cancer: Mechanistic
insights gained from human genomics. Sci Adv. 1:e15004472015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, Sun
G, Lu Z, Huang Y, Yang CG, et al: m6A RNA methylation
regulates the Self-renewal and tumorigenesis of glioblastoma stem
cells. Cell Rep. 18:2622–2634. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hashemi M, Etemad S, Rezaei S, Ziaolhagh
S, Rajabi R, Rahmanian P, Abdi S, Koohpar ZK, Rafiei R, Raei B, et
al: Progress in targeting PTEN/PI3K/Akt axis in glioblastoma
therapy: Revisiting molecular interactions. Biomed Pharmacother.
158:1142042023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen CH, Shaikenov T, Peterson TR,
Aimbetov R, Bissenbaev AK, Lee SW, Wu J, Lin HK and Sarbassov dos
D: ER stress inhibits mTORC2 and Akt signaling through
GSK-3β-mediated phosphorylation of rictor. Sci Signal. 4:ra102011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen W, Liu F, Lin X, Li L, Chen W, Zhang
T, Liu Y, Niu L, Zhang Y and Hu P: Cucurbitacin E inhibits the
proliferation of glioblastoma cells via FAK/AKT/GSK3β pathway.
Oncol Rep. 50:2212023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Şengelen A and Önay-Uçar E: Rosmarinic
acid attenuates glioblastoma cells and spheroids' growth and
EMT/stem-like state by PTEN/PI3K/AKT downregulation and ERK-induced
apoptosis. Phytomedicine. 135:1560602024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mekala JR, Kurappalli RK, Ramalingam P and
Moparthi NR: N-acetyl l-aspartate and Triacetin modulate tumor
suppressor MicroRNA and class I and II HDAC gene expression induce
apoptosis in Glioblastoma cancer cells in vitro. Life Sci.
286:1200242021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Harachi M, Masui K, Honda H, Muragaki Y,
Kawamata T, Cavenee WK, Mischel PS and Shibata N: Dual regulation
of histone methylation by mTOR complexes controls glioblastoma
tumor cell growth via EZH2 and SAM. Mol Cancer Res. 18:1142–1152.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Barrie U, Floyd K, Datta A and Wetzel DM:
MAPK/ERK activation in macrophages promotes Leishmania
internalization and pathogenesis. Microbes Infect. 26:1053532024.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ullah R, Yin Q, Snell AH and Wan L:
RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer
Biol. 85:123–154. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Park AK, Kim P, Ballester LY, Esquenazi Y
and Zhao Z: Subtype-specific signaling pathways and genomic
aberrations associated with prognosis of glioblastoma. Neuro Oncol.
21:59–70. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Angom RS, Mondal SK, Wang F, Madamsetty
VS, Wang E, Dutta SK, Gulani Y, Sarabia-Estrada R, Sarkaria JN,
Quiñones-Hinojosa A and Mukhopadhyay D: Ablation of neuropilin-1
improves the therapeutic response in conventional drug-resistant
glioblastoma multiforme. Oncogene. 39:7114–7126. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li H, Niu X and Cheng R: Prevalence,
prognostic and clinicopathological value of HIF-1α in glioblastoma
patients: A systematic review and meta-analysis. Neurosurg Rev.
47:8602024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Karkon-Shayan S, Aliashrafzadeh H,
Dianat-Moghadam H, Rastegar-Pouyani N, Majidi M, Zarei M,
Moradi-Vastegani S, Bahramvand Y, Babaniamansour S and Jafarzadeh
E: Resveratrol as an antitumor agent for glioblastoma multiforme:
Targeting resistance and promoting apoptotic cell deaths. Acta
Histochem. 125:1520582023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sun J, Wu S, Zhao W, Xue S, Zhang L and
Ren J: MAPK-activated protein kinase 2 is associated with poor
prognosis of glioma patients and immune inhibition in glioma. Front
Oncol. 14:13079922024. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Golovin A, Dzarieva F, Rubetskaya K,
Shamadykova D, Usachev D, Pavlova G and Kopylov A: In silico born
designed Anti-EGFR aptamer gol1 has Anti-proliferative potential
for patient glioblastoma Cells. Int J Mol Sci. 26:10722025.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Geribaldi-Doldán N, Hervás-Corpión I,
Gómez-Oliva R, Domínguez-García S, Ruiz FA, Iglesias-Lozano I,
Carrascal L, Pardillo-Díaz R, Gil-Salú JL, Nunez-Abades P, et al:
Targeting protein Kinase C in glioblastoma treatment. Biomedicines.
9:3812021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hatipoglu OF, Nishinaka T, Nishibori M,
Watanabe M, Toyomura T, Mori S, Yaykasli KO, Wake H and Takahashi
H: Histamine promotes angiogenesis through a histamine H1
receptor-PKC-VEGF-mediated pathway in human endothelial cells. J
Pharmacol Sci. 151:177–186. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang LH, Wu CF, Rajasekaran N and Shin YK:
Loss of tumor suppressor gene function in human cancer: An
overview. Cell Physiol Biochem. 51:2647–2693. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Solt LA and May MJ: The IkappaB kinase
complex: Master regulator of NF-kappaB signaling. Immunol Res.
42:3–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Latour M, Her NG, Kesari S and Nurmemmedov
E: WNT signaling as a therapeutic target for glioblastoma. Int J
Mol Sci. 22:84282021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sedgwick AE and D'Souza-Schorey C: Wnt
signaling in cell motility and invasion: Drawing parallels between
development and cancer. Cancers (Basel). 8:802016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cadigan KM and Waterman ML: TCF/LEFs and
Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol.
4:a0079062012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Desterke C, Fu Y, Bonifacio-Mundaca J,
Monge C, Pineau P, Mata-Garrido J and Francés R: Single-cell RNA
sequencing reveals LEF1-driven wnt pathway activation as a shared
oncogenic program in hepatoblastoma and medulloblastoma. Curr
Oncol. 32:352025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Guan R, Zhang X and Guo M: Glioblastoma
stem cells and Wnt signaling pathway: Molecular mechanisms and
therapeutic targets. Chin Neurosurg J. 6:252020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhou C, Zhao H, Wang S, Dong C, Yang F and
Zhang J: LncRNA ADAMTS9-AS1 knockdown suppresses cell proliferation
and migration in glioma through downregulating Wnt/β-catenin
signaling pathway. Bosn J Basic Med Sci. 22:395–402.
2022.PubMed/NCBI
|
|
70
|
Butler M, Prasad S and Srivastava SK:
Targeting glioblastoma tumor microenvironment. Adv Exp Med Biol.
1296:1–9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
DePalma TJ, Sivakumar H and Skardal A:
Strategies for developing complex multi-component in vitro tumor
models: Highlights in glioblastoma. Adv Drug Deliv Rev.
180:1140672022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Read RD, Tapp ZM, Rajappa P and
Hambardzumyan D: Glioblastoma microenvironment-from biology to
therapy. Genes Dev. 38:360–379. 2024.PubMed/NCBI
|
|
73
|
De Leo A, Ugolini A and Veglia F: Myeloid
cells in glioblastoma microenvironment. Cells. 10:182020.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lakshmanachetty S, Cruz-Cruz J, Hoffmeyer
E, Cole AP and Mitra SS: New insights into the multifaceted role of
Myeloid-derived suppressor cells (MDSCs) in High-grade gliomas:
From metabolic reprograming, immunosuppression, and therapeutic
resistance to current strategies for targeting MDSCs. Cells.
10:8932021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Liu Y, Chen X, Xu Y, Yang T, Wang H, Wang
Z, Hu Z, Chen L, Zhang Z and Wu Y: CTHRC1 promotes colorectal
cancer progression by recruiting tumor-associated macrophages via
up-regulation of CCL15. J Mol Med (Berl). 102:81–94. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ren J, Xu B, Ren J, Liu Z, Cai L, Zhang X,
Wang W, Li S, Jin L and Ding L: The Importance of M1-and
M2-Polarized macrophages in glioma and as potential treatment
targets. Brain Sci. 13:12692023. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Guo M, Zhang J, Han J, Hu Y, Ni H, Yuan J,
Sun Y, Liu M, Gao L, Liao W, et al: VEGFR2 blockade inhibits
glioblastoma cell proliferation by enhancing mitochondrial
biogenesis. J Transl Med. 22:4192024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Jia S, Bode AM, Chen X and Luo X:
Unlocking the potential: Targeting metabolic pathways in the tumor
microenvironment for cancer therapy. Biochim Biophys Acta Rev
Cancer. 1879:1891662024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Agnihotri TG, Salave S, Shinde T, Srikanth
I, Gyanani V, Haley JC and Jain A: Understanding the role of
endothelial cells in brain tumor formation and metastasis: A
proposition to be explored for better therapy. J Natl Cancer Cent.
3:222–235. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Shimizu M, Shirakami Y and Moriwaki H:
Targeting receptor tyrosine kinases for chemoprevention by green
tea catechin, EGCG. Int J Mol Sci. 9:1034–1049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wang C, Liu Y, Zuo Z, Cui D, Xu Y, Li L
and Jiang Y: Dual role of exosomal circCMTM3 derived from GSCs in
impeding degradation and promoting phosphorylation of STAT5A to
facilitate vasculogenic mimicry formation in glioblastoma.
Theranostics. 14:5698–5724. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang F, Liao W, Li C and Zhu L: Silencing
BMAL1 promotes M1/M2 polarization through the LDHA/lactate axis to
promote GBM sensitivity to bevacizumab. Int Immunopharmacol.
134:1121872024. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Schor AM, Woolston AM, Kankova K, Harada
K, Aljorani LE, Perrier S, Felts PA, Keatch RP and Schor SL:
Migration stimulating factor (MSF): Its role in the tumour
microenvironment. Adv Exp Med Biol. 1329:351–397. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhang B, Han X, Gao Q, Liu J, Li S, Zha W,
Wang X, Guo X and Gao D: Enhancer II-targeted dsRNA decreases GDNF
expression via histone H3K9 trimethylation to inhibit glioblastoma
progression. Brain Res Bull. 167:22–32. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Meier C and Bischoff A: Oligodendroglial
cell development in jimpy mice and controls. An
electron-microscopic study in the optic nerve. J Neurol Sci.
26:517–528. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Slepak TI, Guyot M, Walters W, Eichberg DG
and Ivan ME: Dual role of the adhesion G-protein coupled receptor
ADRGE5/CD97 in glioblastoma invasion and proliferation. J Biol
Chem. 299:1051052023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ishii H, Mimura Y, Zahra MH, Katayama S,
Hassan G, Afify SM and Seno M: Isolation and characterization of
cancer stem cells derived from human glioblastoma. Am J Cancer Res.
11:441–457. 2021.PubMed/NCBI
|
|
88
|
Ryskalin L, Gaglione A, Limanaqi F,
Biagioni F, Familiari P, Frati A, Esposito V and Fornai F: The
autophagy status of cancer stem cells in gliobastoma multiforme:
From cancer promotion to therapeutic strategies. Int J Mol Sci.
20:38242019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lathia JD, Mack SC, Mulkearns-Hubert EE,
Valentim CL and Rich JN: Cancer stem cells in glioblastoma. Genes
Dev. 29:1203–1217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Singh DK, Shivalingappa PKM, Sharma A,
Mondal A, Muzumdar D, Shiras A and Bapat SA: NSG-70, a new
glioblastoma cell line with mixed proneural-mesenchymal features,
associates NOTCH1-WNT5A signaling with stem cell maintenance and
angiogenesis. J Neurooncol. 157:575–591. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Comba A, Faisal SM, Varela ML, Hollon T,
Al-Holou WN, Umemura Y, Nunez FJ, Motsch S, Castro MG and
Lowenstein PR: Uncovering spatiotemporal heterogeneity of
High-grade gliomas: From disease biology to therapeutic
implications. Front Oncol. 11:7037642021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Griessmair M, Delbridge C, Ziegenfeuter J,
Jung K, Mueller T, Schramm S, Bernhardt D, Schmidt-Graf F, Kertels
O, Thomas M, et al: Exploring molecular glioblastoma: Insights from
advanced imaging for a nuanced understanding of the molecularly
defined malignant biology. Neurooncol Adv. 6:vdae1062024.PubMed/NCBI
|
|
94
|
Liu M, Ji Z, Jain V, Smith VL, Hocke E,
Patel AP, McLendon RE, Ashley DM, Gregory SG and López GY: Spatial
transcriptomics reveals segregation of tumor cell states in
glioblastoma and marked immunosuppression within the perinecrotic
niche. Acta Neuropathol Commun. 12:642024. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Rojiani AM and Dorovini-Zis K: Glomeruloid
vascular structures in glioblastoma multiforme: An
immunohistochemical and ultrastructural study. J Neurosurg.
85:1078–1084. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Lista S, Imbimbo BP, Grasso M, Fidilio A,
Emanuele E, Minoretti P, López-Ortiz S, Martín-Hernández J, Gabelle
A, Caruso G, et al: Tracking neuroinflammatory biomarkers in
Alzheimer's disease: A strategy for individualized therapeutic
approaches? J Neuroinflammation. 21:1872024. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yang Y, Wang X, Hawkins CA, Chen K,
Vaynberg J, Mao X, Tu Y, Zuo X, Wang J, Wang YX, et al: Structural
basis of focal adhesion localization of LIM-only adaptor PINCH by
integrin-linked kinase. J Biol Chem. 284:5836–5844. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ainslie K: Modifying Post-surgical
immunity: Controlled release of TLR7/8 agonist for immune mediated
clearance of glioblastoma. Res Sq: rs.3.rs-5024510. 2024.doi:
10.21203/rs.3.rs-5024510/v1.
|
|
99
|
Zhang L, Liu Z, Dong Y and Kong L: E2F2
drives glioma progression via PI3K/AKT in a PFKFB4-dependent
manner. Life Sci. 276:1194122021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Li J, Chen Q, Xu S, Wu J, Huang Q, Song P
and Duan F: Down-regulation of BAG3 inhibits proliferation and
promotes apoptosis of glioblastoma multiforme through
BAG3/HSP70/HIF-1α signaling pathway. Int J Clin Exp Pathol.
11:4305–4318. 2018.PubMed/NCBI
|
|
101
|
Zhang L, He J, Zhao W, Zhou Y, Li J, Li S,
Zhao W, Zhang L, Tang Z, Tan G, et al: CD2AP promotes the
progression of glioblastoma multiforme via TRIM5-mediated NF-kB
signaling. Cell Death Dis. 15:7222024. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Taheri E and Raeeszadeh-Sarmazdeh M:
Effect of TIMPs and their minimally engineered variants in blocking
invasion and migration of brain cancer cells. bioRxiv.
2024.06.05.597644. 2024.
|
|
103
|
Ghaffari SH, Yousefi M, Dizaji MZ, Momeny
M, Bashash D, Zekri A, Alimoghaddam K and Ghavamzadeh A: Arsenic
trioxide induces apoptosis and incapacitates proliferation and
invasive properties of U87MG glioblastoma cells through a possible
NF-κB-Mediated mechanism. Asian Pac J Cancer Prev. 17:1553–1564.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Pham LC, Weller L, Gann CN, Schumacher KM,
Vlassak S, Swanson T, Highsmith K, O'Brien BJ, Nash S, Aaroe A, et
al: Prolonged complete response to adjuvant tepotinib in a patient
with newly diagnosed disseminated glioblastoma harboring
mesenchymal-epithelial transition fusion. Oncologist.
30:oyae1002025. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Huang Z, Wang M, Chen Y, Tang H, Tang K,
Zhao M, Yang W, Zhou Z, Tian J, Xiang W, et al:
Glioblastoma-derived migrasomes promote migration and invasion by
releasing PAK4 and LAMA4. Commun Biol. 8:912025. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Magalhaes YT and Forti FL: ROCK inhibition
reduces the sensitivity of mutant p53 glioblastoma to genotoxic
stress through a Rac1-driven ROS production. Int J Biochem Cell
Biol. 164:1064742023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Mulherkar S and Tolias KF: RhoA-ROCK
signaling as a therapeutic target in traumatic brain injury. Cells.
9:2452020. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Velasquez C, Gutierrez O, Carcelen M and
Fernandez-Luna JL: The invasion factor ODZ1 is upregulated through
an epidermal growth factor Receptor-induced pathway in primary
glioblastoma cells. Cells. 13:662024. View Article : Google Scholar
|
|
109
|
Xue Y, Bi F, Zhang X, Zhang S, Pan Y, Liu
N, Shi Y, Yao X, Zheng Y and Fan D: Role of Rac1 and Cdc42 in
hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha
activation. Int J Cancer. 118:2965–2972. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Shi C, Luo W, Sun C, Yu L, Zhou X, Hua D,
Jiang Z, Wang Q and Yu S: The miR-29 family members induce
glioblastoma cell apoptosis by targeting cell division cycle 42 in
a p53-dependent manner. Eur J Clin Invest. 53:e139642023.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yin X, Xia K, Peng S, Tan B, Huang Y, Wang
M and He M: ABCF1/CXCL12/CXCR4 enhances glioblastoma cell
proliferation, migration, and invasion by activating the PI3K/AKT
signal pathway. Dev Neurosci. 46:210–220. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Horowitz MA, Ghadiyaram A, Mehkri Y,
Chakravarti S, Liu J, Fox K, Gendreau J and Mukherjee D: Surgical
resection of glioblastoma in the very elderly: An analysis of
survival outcomes using the surveillance, epidemiology, and end
results database. Clin Neurol Neurosurg. 245:1084692024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Montemurro N, Fanelli GN, Scatena C,
Ortenzi V, Pasqualetti F, Mazzanti CM, Morganti R, Paiar F,
Naccarato AG and Perrini P: Surgical outcome and molecular pattern
characterization of recurrent glioblastoma multiforme: A
single-center retrospective series. Clin Neurol Neurosurg.
207:1067352021. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Vanhove C and Goethals I: Magnetic
resonance imaging-guided radiation therapy using animal models of
glioblastoma. Br J Radiol. 92:201807132019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Li R, Wang H, Liang Q, Chen L and Ren J:
Radiotherapy for glioblastoma: Clinical issues and nanotechnology
strategies. Biomater Sci. 10:892–908. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Ashby LS, Smith KA and Stea B: Gliadel
wafer implantation combined with standard radiotherapy and
concurrent followed by adjuvant temozolomide for treatment of newly
diagnosed high-grade glioma: A systematic literature review. World
J Surg Oncol. 14:2252016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
LiverTox, . Clinical and Research
Information on Drug-Induced Liver Injury. National Institute of
Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2012
|
|
118
|
Ou A, Yung WKA and Majd N: Molecular
mechanisms of treatment resistance in glioblastoma. Int J Mol Sci.
22:3512020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Dymova MA, Kuligina EV and Richter VA:
Molecular mechanisms of drug resistance in glioblastoma. Int J Mol
Sci. 22:63852021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Yu Y, Wang A, Wang S, Sun Y, Chu L, Zhou
L, Yang X, Liu X, Sha C, Sun K and Xu L: Efficacy of
Temozolomide-conjugated gold nanoparticle photothermal therapy of
Drug-resistant glioblastoma and its mechanism study. Mol Pharm.
19:1219–1229. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Sherman JH, Bobak A, Arsiwala T, Lockman P
and Aulakh S: Targeting drug resistance in glioblastoma (Review).
Int J Oncol. 65:802024. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Asija S, Chatterjee A, Yadav S, Chekuri G,
Karulkar A, Jaiswal AK, Goda JS and Purwar R: Combinatorial
approaches to effective therapy in glioblastoma (GBM): Current
status and what the future holds. Int Rev Immunol. 41:582–605.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Lv W, Yang F, Ge Z, Xin L, Zhang L, Zhai
Y, Liu X, Guo Q, Mao X, Luo P, et al: Aberrant overexpression of
myosin 1b in glioblastoma promotes angiogenesis via VEGF-myc-myosin
1b-Piezo1 axis. J Biol Chem. 300:1078072024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Yuan Z: From origin to present:
Establishment, mechanism, evolutions and biomedical applications of
CRISPR/Cas-based Macromolecular System in Brief. Biol Biotechnol.
2024.doi: 10.20944/preprints202408.1715.v2.
|
|
125
|
Fang Y, Li X and Tian R: Unlocking
glioblastoma vulnerabilities with CRISPR-Based genetic screening.
Int J Mol Sci. 25:57022024. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Chow RD, Guzman CD, Wang G, Schmidt F,
Youngblood MW, Ye L, Errami Y, Dong MB, Martinez MA, Zhang S, et
al: AAV-mediated direct in vivo CRISPR screen identifies functional
suppressors in glioblastoma. Nat Neurosci. 20:1329–1341. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Tu KJ, Stewart CE, Hendrickson PG, Regal
JA, Kim SY, Ashley DM, Waitkus MS and Reitman ZJ: Pooled genetic
screens to identify vulnerabilities in TERT-promoter-mutant
glioblastoma. Oncogene. 42:3274–3286. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Lin P, Chen W, Long Z, Yu J, Yang J, Xia
Z, Wu Q, Min X, Tang J, Cui Y, et al: RBBP6 maintains glioblastoma
stem cells through CPSF3-dependent alternative polyadenylation.
Cell Discov. 10:322024. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Waldman AD, Fritz JM and Lenardo MJ: A
guide to cancer immunotherapy: From T cell basic science to
clinical practice. Nat Rev Immunol. 20:651–668. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Farahzadi R, Fathi E, Vandghanooni S and
Valipour B: Hydrogel encapsulation of mesenchymal stem
cells-derived extracellular vesicles as a novel therapeutic
approach in cancer therapy. Biochim Biophys Acta Rev Cancer.
1879:1891772024. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Guo Y, Hu D, Lian L, Zhao L, Li M, Bao H
and Xu S: Stem Cell-derived extracellular vesicles: A promising
nano delivery platform to the brain? Stem Cell Rev Rep. 19:285–308.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Luksik AS, Yazigi E, Shah P and Jackson
CM: CAR T cell therapy in glioblastoma: Overcoming challenges
related to antigen expression. Cancers (Basel). 15:14142023.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Xie HY, Mao M, Lei Y and Ma X: Challenges
and emerging strategies of immunotherapy for glioblastoma.
Chembiochem. e2024008482025.doi: 10.1002/cbic.202400848 (Epub ahead
of print). View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Quan Q, Guo L, Huang L, Liu Z, Guo T, Shen
Y, Ding S, Liu C and Cao L: Expression and clinical significance of
PD-L1 and infiltrated immune cells in the gastric adenocarcinoma
microenvironment. Medicine (Baltimore). 102:e363232023. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Mamdani H, Matosevic S, Khalid AB, Durm G
and Jalal SI: Immunotherapy in lung cancer: Current landscape and
future directions. Front Immunol. 13:8236182022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ribatti D, Cazzato G, Tamma R, Annese T,
Ingravallo G and Specchia G: Immune checkpoint inhibitors targeting
PD-1/PD-L1 in the treatment of human lymphomas. Front Oncol.
14:14209202024. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Maghrouni A, Givari M, Jalili-Nik M,
Mollazadeh H, Bibak B, Sadeghi MM, Afshari AR, Johnston TP and
Sahebkar A: Targeting the PD-1/PD-L1 pathway in glioblastoma
multiforme: Preclinical evidence and clinical interventions. Int
Immunopharmacol. 93:1074032021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Sarkar S, Greer J, Marlowe NJ, Medvid A,
Ivan ME, Kolishetti N and Dhar S: Stemness, invasion, and
immunosuppression modulation in recurrent glioblastoma using
nanotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol.
16:e19762024. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Sousa F: Emerging cytokine delivery with
nanomedicine for brain cancer treatment. Expert Opin Drug Deliv.
21:513–516. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Hameedat F, Mendes BB, Conniot J, Di
Filippo LD, Chorilli M, Schroeder A, Conde J and Sousa F:
Engineering nanomaterials for glioblastoma nanovaccination. Nat Rev
Materials. 9:628–642. 2024. View Article : Google Scholar
|
|
141
|
Lim SH, Yee GT and Khang D:
Nanoparticle-based combinational strategies for overcoming the
Blood-brain barrier and Blood-tumor barrier. Int J Nanomedicine.
19:2529–2552. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Song M, Tian J, Wang L, Dong S, Fu K, Chen
S and Liu C: Efficient delivery of lomitapide using hybrid
Membrane-coated tetrahedral DNA nanostructures for glioblastoma
therapy. Adv Mater. 36:e23117602024. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Song Z, Zhao L, Fang W, Guo S, Xu A, Zhan
Z, Cai Y, Xue SS, Chai P, Jiang Q, et al: Glioma cell membrane
camouflaged cinobufotalin delivery system for combinatorial
orthotopic glioblastoma therapy. Nano Res. 16:11164–11175. 2023.
View Article : Google Scholar
|
|
144
|
Ruan W, Xu S, An Y, Cui Y, Liu Y, Wang Y,
Ismail M, Liu Y and Zheng M: Brain-Targeted Cas12a
ribonucleoprotein nanocapsules enable synergetic gene Co-editing
leading to potent inhibition of orthotopic glioblastoma. Adv Sci
(Weinh). 11:e24021782024. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
et al: Effect of tumor-treating fields plus maintenance
temozolomide vs maintenance temozolomide alone on survival in
patients with glioblastoma: A randomized clinical trial. JAMA.
318:2306–2316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Rominiyi O, Vanderlinden A, Clenton SJ,
Bridgewater C, Al-Tamimi Y and Collis SJ: Tumour treating fields
therapy for glioblastoma: Current advances and future directions.
Br J Cancer. 124:697–709. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Khagi S, Kotecha R, Gatson NTN, Jeyapalan
S, Abdullah HI, Avgeropoulos NG, Batzianouli ET, Giladi M,
Lustgarten L and Goldlust SA: Recent advances in tumor treating
fields (TTFields) therapy for glioblastoma. Oncologist. Oct
14;oyae227, 2024 doi: 10.1093/oncolo/oyae227 (Epub ahead of print).
PubMed/NCBI
|
|
148
|
Chen D, Le SB, Hutchinson TE, Calinescu
AA, Sebastian M, Jin D, Liu T, Ghiaseddin A, Rahman M and Tran DD:
Tumor treating fields dually activate STING and AIM2 inflammasomes
to induce adjuvant immunity in glioblastoma. J Clin Invest.
132:e1492582022. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Hendricks-Wenger A, Hutchison R,
Vlaisavljevich E and Allen IC: Immunological effects of histotripsy
for cancer therapy. Front Oncol. 11:6816292021. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Sørensen BS and Horsman MR: Tumor hypoxia:
Impact on radiation therapy and molecular pathways. Front Oncol.
10:5622020. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
El Kaffas A, Gangeh MJ, Farhat G, Tran WT,
Hashim A, Giles A and Czarnota GJ: Tumour vascular shutdown and
cell death following Ultrasound-microbubble enhanced radiation
therapy. Theranostics. 8:314–327. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
D'Ammando A, Raspagliesi L, Gionso M,
Franzini A, Porto E, Di Meco F, Durando G, Pellegatta S and Prada
FJ: Sonodynamic therapy for the treatment of intracranial gliomas.
J Clin Med. 10:11012021. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Verma J, Lal S and Van Noorden CJ:
Nanoparticles for hyperthermic therapy: Synthesis strategies and
applications in glioblastoma. Int J Nanomedicine. 9:2863–2877.
2014.PubMed/NCBI
|
|
154
|
Rego GNA, Nucci MP, Mamani JB, Oliveira
FA, Marti LC, Filgueiras IS, Ferreira JM, Real CC, Faria DP,
Espinha PL, et al: Therapeutic efficiency of multiple applications
of magnetic hyperthermia technique in glioblastoma using
aminosilane coated iron oxide nanoparticles: In vitro and in vivo
study. Int J Mol Sci. 21:9582020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Tabatabaei SN, Tabatabaei MS, Girouard H
and Martel S: Hyperthermia of magnetic nanoparticles allows passage
of sodium fluorescein and Evans blue dye across the blood-retinal
barrier. Int J Hyperthermia. 32:657–665. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Qi G, Chen K, Guan W, Xie J, Chen X, Zhang
G, Yan R and Yang G: One-Pot synthesis of a pH-Sensitive MOF
integrated with glucose oxidase for amplified tumor
Photodynamic/Photothermal therapy. ACS Appl Mater Interfaces.
16:613952024. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Lim KY, Won JK, Park CK, Kim SK, Choi SH,
Kim T, Yun H and Park SH: H3 G34-mutant high-grade glioma. Brain
Tumor Pathol. 38:4–13. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Goldman MJ, Baskin AM, Sharpe MA and
Baskin DS: Advances in gene therapy for high-grade glioma: A review
of the clinical evidence. Expert Rev Neurother. 24:879–895. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Xing Z, Jiang X, Chen Y, Wang T, Li X, Wei
X, Fan Q, Yang J, Wu H, Cheng J and Cai R: Glutamine deprivation in
glioblastoma stem cells triggers autophagic SIRT3 degradation to
epigenetically restrict CD133 expression and stemness. Apoptosis.
29:1619–1631. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Garros-Regulez L, Aldaz P, Arrizabalaga O,
Moncho-Amor V, Carrasco-Garcia E, Manterola L, Moreno-Cugnon L,
Barrena C, Villanua J, Ruiz I, et al: mTOR inhibition decreases
SOX2-SOX9 mediated glioma stem cell activity and temozolomide
resistance. Expert Opin Ther Targets. 20:393–405. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Bouchart C, Trépant AL, Hein M, Van Gestel
D and Demetter P: Prognostic impact of glioblastoma stem cell
markers OLIG2 and CCND2. Cancer Med. 9:1069–1078. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Anido J, Sáez-Borderías A, Gonzàlez-Juncà
A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I,
Martínez-Sáez E, Prudkin L, et al: TGF-β receptor inhibitors target
the CD44(high)/Id1(high) Glioma-initiating cell population in human
glioblastoma. Cancer Cell. 18:655–668. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Tchoghandjian A, Baeza N, Colin C, Cayre
M, Metellus P, Beclin C, Ouafik L and Figarella-Branger D: A2B5
cells from human glioblastoma have cancer stem cell properties.
Brain Pathol. 20:211–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Huang YK, Wang TM, Chen CY, Li CY, Wang
SC, Irshad K, Pan Y and Chang KC: The role of ALDH1A1 in
glioblastoma proliferation and invasion. Chem Biol Interact.
402:1112022024. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Kiefel H, Bondong S, Hazin J, Ridinger J,
Schirmer U, Riedle S and Altevogt P: L1CAM: A major driver for
tumor cell invasion and motility. Cell Adh Migr. 6:374–384. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Selvaraj S, Srinivas BH, Verma SK and Ms
G: Significance of Nestin and CD133 as cancer stem cell markers in
diffuse glioma and association with p53 expression and IDH status.
Int J Clin Exp Pathol. 17:208–218. 2024. View Article : Google Scholar : PubMed/NCBI
|
